R32 Insurance Policy Changes

ICD-10 R32 is officially defined as "Unspecified urinary incontinence." code R32 is referenced in 11 tracked payer policy changes from Excellus BlueCross BlueShield, Health Net, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R32 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Mar 19, 2026Medium impact
Pelvic Floor Electrical Stimulation as a Treatment for Urinary or Fecal Incontinence 1.01.19
Excellus BlueCross BlueShield policy 1.01.19 considers pelvic floor electrical stimulation (PFES) not medically necessary as a treatment for urinary or fecal incontinence. The policy states that published randomized controlled trials have reported inconsistent or inconclusive results. It also states that evidence is insufficient to determine the effectiveness of PFES for urinary or fecal incontinence, or to show that it is more effective than pelvic floor muscle exercises or sham simulation. This version is effective March 19, 2026, and its annual review kept the policy intent unchanged.
Health Net · Identified Sep 25, 2026Medium impact
26-1101m Updates to Clinical Policies – August 2026
CalViva Health (Health Net's Medi-Cal plan in California) updated seven clinical policies, with the source stating they were approved for and effective in August 2026, so those changes are already in effect. The changes add or delete diagnosis and CPT codes for urodynamic testing, genitourinary and GI pathogen panels, narrow the criteria for selective nerve root blocks and epidural steroid injections, and tighten documentation rules for applied behavior analysis services.
Health Net · Identified Sep 25, 2026Medium impact
26-1102m Updates to Clinical Policies – August 2026
Community Health Plan of Imperial Valley (a Medi-Cal plan in Imperial County, California) updated seven clinical policies, with the source stating they were approved for and effective in August 2026, so those changes are already in effect. The changes add or delete diagnosis and CPT codes for urodynamic testing, genitourinary and GI pathogen panels, narrow the criteria for selective nerve root blocks and epidural steroid injections, and tighten documentation rules for applied behavior analysis services.
Health Net · Identified Sep 25, 2026Medium impact
26-1103m Updates to Clinical Policies – August 2026
Health Net's August 2026 clinical policy update changes medical necessity criteria and code lists in several policies. The biggest change is that selective nerve root blocks are now for diagnostic purposes only, with therapeutic indications removed, and the notice also updates ICD-10 and CPT lists for urodynamic testing, GI pathogen panels, vaginitis testing and vagus nerve stimulation. The notice gives no day-level effective date beyond August 2026, so treat these changes as already in effect and check the full policies in the Provider Library.
Aetna · Identified Aug 19, 2026Medium impact
YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)
Aetna considers Nd:YAG laser capsulotomy medically necessary after cataract extraction in members with visually significant clouding of the posterior capsule, and considers Nd:YAG laser peripheral iridotomy medically necessary for acute primary angle closure, primary angle-closure glaucoma, plateau iris syndrome, aqueous misdirection, and before intraocular lens insertion into the anterior chamber to avoid post-operative iris bombe or pupil block. Capsulotomy performed within 6 months of cataract surgery is subject to medical necessity review, and it is considered experimental, investigational, or unproven if none of the stated criteria is met. Nd:YAG laser vitreolysis for vitreous floaters, posterior hyaloidotomy for pre-macular hemorrhage, goniopuncture for failed trabeculectomy, and peripheral iridotomy to prevent pigment dispersion glaucoma are considered experimental, investigational, or unproven, as are many non-ophthalmological uses such as basal cell carcinoma, benign prostatic hyperplasia, onychomycosis and snoring.
Aetna · Identified Aug 18, 2026Medium impact
Urological Supplies (CPB 0533, reviewed 2026-07-30)
Aetna covers urinary catheters and external urinary collection devices as medically necessary prosthetics for members with permanent urinary incontinence or permanent urinary retention, where retention is not expected to be medically or surgically corrected within 3 months. Aetna considers one indwelling catheter per month medically necessary for routine catheter maintenance, and the policy lists usual maximum quantities for insertion trays, drainage bags, intermittent catheters, lubricant and external collection devices. The inFlow device is considered medically necessary as an alternative to intermittent catheterization for permanent urinary retention due to impaired detrusor contractility, with one device no more than once every 29 days, and the PureWick urine collection system is considered unproven and not medically necessary for the management of urinary incontinence.
Aetna · Identified Aug 18, 2026Medium impact
Urinary Incontinence (CPB 0223, reviewed 2026-07-16)
Aetna Clinical Policy Bulletin 0223 on urinary incontinence, reviewed 2026-07-16, considers multi-channel urodynamic studies medically necessary when a member has both symptoms and physical findings of urinary incontinence or voiding dysfunction and the provider is considering invasive, potentially morbid or irreversible treatment after conservative management has failed. It considers medically necessary the artificial urinary sphincter, FDA-cleared peri-urethral bulking agents, permanent sacral nerve stimulators after temporary trial stimulation, percutaneous tibial nerve stimulation, weighted vaginal cones, pessaries, tension-free and transobturator tape procedures, colposuspension and sub-urethral sling procedures when the stated criteria are met. Bilateral permanent sacral nerve stimulator implantation, the Genityte and FemiLift laser procedures, stem cell therapy and many other listed interventions are considered experimental, investigational or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) (CPB 0330, reviewed 2026-05-20)
Aetna considers the multiple sleep latency test (MSLT) and maintenance of wakefulness test (MWT) medically necessary to evaluate symptoms of narcolepsy to confirm the diagnosis, and for suspected idiopathic hypersomnia to help differentiate it from narcolepsy. A repeat MSLT or MWT is medically necessary only if the initial test was invalid or uninterpretable, was affected by extraneous circumstances or lacked study conditions, or the patient is suspected to have narcolepsy and an earlier test did not provide polygraphic confirmation. Home MSLT and single nap studies are experimental, investigational or unproven, as are these tests for other indications, including attention-deficit/hyperactivity disorder, chronic fatigue syndrome, insomnia, obstructive sleep apnea syndrome, restless leg syndrome, psychiatric hypersomnolence, and neurologic disorders other than narcolepsy such as dementia and Parkinson's disease.
Aetna · Identified Aug 12, 2026Medium impact
Organ Prolapse: Selected Procedures (CPB 0858, reviewed 2025-12-24)
Aetna considers dynamic MRI in persons with complex organ prolapse to supplement the physical examination, laparoscopic suture rectopexy for rectal prolapse, Le Fort colpocleisis for severe utero-vaginal prolapse in elderly and chronically ill persons who no longer desire coital function, sacrocolpopexy for vaginal apical prolapse repair, and tension-free vaginal tape for pelvic organ prolapse complicated by stress urinary incontinence medically necessary. Aetna considers biodegradable cog threads, biologic grafts for vaginal apical prolapse, combined laparoscopic-vaginal lateral suspension, pectopexy, laser therapy, transcutaneous electrical nerve stimulation, trans-vaginal absorbable meshes or biological grafts, vNOTES presacral-uterosacral hysteropexy, vNOTES uterosacral ligament suspension, vaginal tactile imaging, and genetic testing experimental, investigational, or unproven for pelvic organ prolapse. The covered CPT codes apply when the selection criteria are met, and specific CPT, HCPCS and ICD-10 codes are listed as not covered for the indications in the policy.
Aetna · Identified Aug 12, 2026Medium impact
Ablative Procedures for Prostate Cancer (CPB 0843, reviewed 2026-02-25)
Aetna considers the listed ablative procedures for prostate cancer experimental, investigational, or unproven for primary or salvage treatment because their effectiveness has not been established. The list includes MRI-guided focal laser ablation, MRI-guided transurethral ultrasound ablation (TULSA), irreversible electroporation, vascular targeted photodynamic therapy, transperineal focal laser ablation, water vapor thermotherapy, dual-fiber laser ablation, and metastasis-directed therapy for oligo-metastatic or oligo-progressive prostate cancer. The listed CPT and HCPCS codes are not covered for the indications listed in the policy, and the listed ICD-10 codes C61, N39.0 through N39.9, R32 and Z19.2 are not covered for the indications listed in the policy.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Carbon-coated spheres, calcium hydroxylapatite, polyacrylamide hydrogel, or polydimethylsiloxane may be considered medically necessary to treat stress urinary incontinence in men and women who have failed appropriate conservative therapy. Autologous cellular therapy, autologous fat, autologous ear chondrocytes, and any other periurethral bulking agent, including Teflon, are investigational for stress urinary incontinence. Periurethral bulking agents for urge urinary incontinence and perianal bulking agents for fecal incontinence are also investigational.

Watch R32

Get one email when a payer policy names R32, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code R32?

There are 11 tracked policy changes affecting code R32, including updates from Excellus BlueCross BlueShield, Health Net, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R32?

Payers that have issued tracked updates for code R32 include: Excellus BlueCross BlueShield, Health Net, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code R32 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R32. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R32?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pelvic Floor Electrical Stimulation as a Treatment for Urinary or Fecal Incontinence 1.01.19

26-1101m Updates to Clinical Policies – August 2026

26-1102m Updates to Clinical Policies – August 2026

26-1103m Updates to Clinical Policies – August 2026

YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)

Urological Supplies (CPB 0533, reviewed 2026-07-30)

Urinary Incontinence (CPB 0223, reviewed 2026-07-16)

Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) (CPB 0330, reviewed 2026-05-20)

Organ Prolapse: Selected Procedures (CPB 0858, reviewed 2025-12-24)

Ablative Procedures for Prostate Cancer (CPB 0843, reviewed 2026-02-25)

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

What insurance policy changes affect code R32?

Which payers have updated policy for code R32?

How do I get notified when code R32 policy changes?

Why do payers change policies for code R32?